Clinical Cancer Research Prevention Award Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Clinical Cancer Research Vol. 6, 3600-3606, September 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax Expression in Invasive and in Situ Squamous Cell Carcinoma of the Uterine Cervix1

Enrico Giarnieri,Rita Mancini,Tiziana Pisani,Mauro Alderisio, andAldo Vecchione 2 ;

Department of Experimental Medicine and Pathology, Cytopathology, School of Medicine, University of Rome La Sapienza, 00161 Rome, Italy


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
To analyze relevant factors and their effects on neoplastic progression in cervical carcinoma, a panel of genetic markers was studied. Paraffin-embedded tissue sections were obtained from 37 patients with carcinoma of the uterine cervix, 14 noninvasive squamous cell carcinomas (NISCCs), and 23 invasive squamous cell carcinomas (ISCCs). Immunoreactivity of Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax proteins was examined by immunohistochemical staining with appropriate antibodies. Positive staining of Msh2 was detected in 13 of 14 (92.9%) NISCCs and in 13 of 23 (56.5%) ISCCs (P < 0.02). Mlh1 immunoreactivity was observed in 10 of 14 (71.4%) NISCCs and in 8 of 23 (34.8%) ISCCs (P < 0.04). Overexpression of p53 protein was found in 4 of 14 (28.6%) NISCCs and in 16 of 23 (69.6%) ISCCs (P < 0.02). Bcl-2 overexpression was detected in 2 of 14 (14.3%) NISCCs and in 15 of 23 (65.2%) ISCCs (P < 0.003). No significant difference in the two types of lesion was found for Bax and Fhit expression. The relationship between Mlh1, Msh2, and p53 protein expression was significant (P < 0.001 and P < 0.001, respectively), as was that between Fhit and Bax immunoreactivity (P < 0.02). In conclusion, we consider that altered expression of Msh2, Mlh1, p53, and Bcl-2 may be a critical event during cervical cancer progression, whereas Fhit may be a component of a proapoptotic pathway.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Since the introduction of cytological screening in the 1940s, the incidence of cervical carcinoma has declined in many developed countries (1) . Considerable efforts have been made to classify preneoplastic and neoplastic lesions (2) , and an association between HPV3 infection, especially high-risk HPV types 16 and 18, and the development of precancerous lesions has been proposed (3, 4, 5, 6) . Nevertheless, prospective studies of cervical neoplasia suggest that HPV infection alone is not responsible for tumor development (7 , 8) .

MMR genes Msh2 and Mlh1, located respectively on chromosomes 2p21–22 and 3p21, are involved in tumors that develop in patients with hereditary nonpolyposis colon cancer (9) ; germ-line mutations of MMR genes are responsible for the replication error-positive phenotype and microsatellite instability (9, 10, 11) . Cells with defective MMR function show a mutator phenotype characterized by an increased mutation rate (12) .

Deletions in the FHIT gene located on chromosome 3p14.2 have been observed in several types of tumor, particularly those resulting from exposure to environmental carcinogens such as lung, kidney, esophageal, head and neck, stomach, and cervical cancer. A possible role as a tumor suppressor gene has been considered (13 , 14) .

The p53 gene located on chromosome 17 encodes a Mr 53,000 protein that is involved in cell growth regulation is frequently found to be mutated in human cancers. In addition, p53 can induce apoptosis in some cells and can down-regulate Bcl-2 (15) . Cells expressing mutant p53 have lost the ability to arrest the cycle and show enhanced genomic instability (16) .

It is commonly accepted that apoptosis is important in the death of normal and neoplastic cells (17) . It has become clear that carcinogenesis can be caused by loss of growth suppression and changes in apoptotic cell death pathways (17 , 18) . Members of the gene family that includes BCL-2 and BAX are involved in the control of apoptosis in a range of different cell types. The BCL-2 gene was cloned initially from a t(14;18) translocation in a follicular B-cell lymphoma (19) . The overexpression of Bcl-2 seems to be associated with the blocking of apoptosis (20) . The ability of Bcl-2 to inhibit apoptosis is dependent on expression of Bcl-2 and on the formation of hetero- and homodimers between members of the Bcl-2 family (21) . On the other hand, the BAX gene is an apoptosis-promoting member of the BCL-2 gene family, and apoptosis is known to be accelerated when the BAX function is predominant (22) . The aim of the current study was to investigate the relationship among expressions of MMR proteins Msh2 and Mlh1, Fhit, p53, Bcl-2, and Bax by immunohistochemistry in ISCC and in situ SCC.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tissue Specimens.
Cervical tissue from archival paraffin blocks was available from 37 patients, 14 of whom had in situ carcinoma and 23 ISCC, according to the WHO grading histopathological classification. Eight cases were well differentiated (G1), 12 cases were moderately differentiated (G2), and three cases were poorly differentiated. The 23 cases were at stage Ib of the FIGO classification (International Federation of Gynaecology Obstetrics). The mean age of patients was 47.79 (SD, ±11.62; range, 31–77 years). Informed consent was obtained from each subject after the purpose and nature of the study had been explained.

Immunohistochemistry.
Sections 5 µm thick were cut onto silanized glass slides and air-dried overnight at room temperature. Sections were dewaxed in xylene and rehydrated through graded alcohol. Incubating the slides for 10 min in 3% hydrogen peroxide quenched endogenous peroxidase activity. Sections for microwave antigen retrieval pretreatment (Fhit, p53, Msh2, and Mlh1 antibodies) were immersed in citrate buffer (Antigen Retrieval; Biogenex, San Ramon, CA). They were irradiated twice in a domestic microwave oven (800 W) at full power for 4 min and then left to cool for 15 min in the hot buffer at room temperature. All primary antibodies used are reported in the Table 1Citation (Fhit antiserum was generously provided by Dr. Kay Huebner, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA). All sections were immunostained with the universal labeled streptavidin-biotin method (Immunotech) according to the manufacturer’s instructions. Positive staining was detected with diaminobenzidine substrate solution, and nuclei were counterstained with hematoxylin.


View this table:
[in this window]
[in a new window]

  		Table 1 Summary of specific antisera and immunohistochemistry conditions

 
Interpretation of Immunoreactivity.
The immunoreactivity was classified as follows: -, 0; +, weak with <10% positive cells; ++, >10% but <50% strongly positive cells; and +++, >50% strongly positive cells. Negative immunoreactivity was scored as either - or +, and positive immunostaining as ++ or +++ (23) . Slides were scored independently by two pathologists; the discordant cases were reviewed and reassigned scores based on consensus of opinion.

Statistical Analysis.
The statistical correlation among Msh2, Mlh1, Fhit, p53, Bax, and Bcl-2 protein expression and histopathological features were analyzed by Fisher’s exact and Spearman’s rank (r) correlation coefficient (SPSS version 7.5.2, Chicago, IL; 1996). The statistical significance was set at P < 0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Immunohistochemical Analysis of Protein Expression.
Msh2 and Mlh1 protein expression was exclusively nuclear. Positive staining of Msh2 was detected in 13 of 14 (92.9%) NISCCs and in 13 of 23 (56.5%) ISCCs. Mlh1 immunoreactivity was observed in 10 of 14 (71.4%) NISCCs and in 8 of 23 (34.8%) ISCCs (Fig. 1)Citation .



View larger version (118K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Lack of Mlh1 nuclear protein expression in an invasive cervical cancer case showing immunoreactivity in dysplastic tissue (x200).

 
Fhit protein expression was prevalently cytoplasmic (Fig. 2)Citation . Strong expression was detected in 2 of 23 (8.7%) ISCC cases, moderate in 6 of 23 (26%) ISCCs and 6 of 14 (42.9%) NISCCs, and low immunoreactivity in 8 of 14 (57.1%) NISCC cases. Fifteen of 23 (65.2%) ISCC cases proved negative.



View larger version (110K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Fhit cytoplasmatic protein expression in invasive cervical carcinoma shows immunoreactivity in koilocytosis dysplastic tissue but not in invasive margin (x200).

 
Nuclear staining for p53 immunoreactivity was detected (Fig. 3)Citation . Eleven of 23 (47.8%) ISCCs and 4 of 14 (28.6%) NISCCs cases showed strong expression, 5 of 23 (21.7%) ISCC cases were found to have moderate positivity, whereas low expression was found in 4 of 23 (17.4%) ISCCs and 10 of 14 (71.4%) NISCC cases. Three of 23 (13%) ISCC cases were negative. Normal cervical epithelium adjacent to tumor did not stain overexpression of p53 protein.



View larger version (115K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. p53 overexpression in invasive cervical cancer (x400).

 
Immunostaining specific for Bax was cytoplasmic. Five of 23 (21.7%) ISCC and 10 of 14 (71.4%) NISCC cases showed strong positive expression. Moderate positive staining was found in 6 of 23 (26%) ISCC cases. Low expression was found in 10 of 23 (43.4%) ISCC and 2 of 14 (14.3%) NISCC cases. Two of 23 (8.7%) ISCC and 2 of 14 (14.3%) NISCC cases were found.

Immunostaining for Bcl-2 was prevalently cytoplasmic. Eight of 23 (34.8%) ISCC cases showed strong expression, whereas 7 of 23 (30.4%) ISCC and 2 of 14 (14.3%) NISCC cases showed moderate expression. Low expression was found in 1 of 23 (4.3%) ISCC and 10 of 14 (71.4%) NISCC cases. Seven of 23 (30.4%) ISCC and 2 of 14 (14.3%) NISCC cases were negative.

Expression of Specific Proteins and Histological Tumor Grading.
Msh2 and Mlh1 expression correlated significantly with NISCC (P < 0.02 and P < 0.04, respectively; Table 2Citation ); p53 and Bcl-2 overexpression was found to be significantly correlated with ISCC versus NISCC (P < 0.02; P < 0.003, respectively; Table 3Citation ), whereas no significant relationship was observed between other biological markers and histopathological features. No significant correlation was observed among histopathological grading and biological markers.


View this table:
[in this window]
[in a new window]

  		Table 2 p53, Msh2, and Mlh1 expression in cervical carcinoma

 

View this table:
[in this window]
[in a new window]

  		Table 3 Fhit, Bax, and Bcl-2 expression in cervical carcinoma

 
Statistical analysis between biological markers showed significant correlation between Msh2 and Mlh1 protein absence and overexpression of p53 [r = -0.481; r = -0.513 (P < 0.001 and P < 0.001, respectively)]. The relationship between Fhit protein expression and Bax was also statistically significant: [r = 0.344 (P < 0.02)]. No correlation was found for any other parameters.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Inactivation of DNA repair genes results in an increased rate of mutation in gatekeeper genes that control cell proliferation and death (24) , increase in genomic instability (25) , and acceleration of tumorigenesis (26) . Defects in the MMR genes Msh2 and Mlh1 were detected in hereditary nonpolyposis colon cancer patients and in some sporadic colorectal cancer, and no expression of either Msh2 and Mlh1 protein has been reported in tumors with microsatellite instability (27 , 28) . In cervical cancer, the literature reported different results with regard to microsatellite instability and mutator phenotype (29, 30, 31, 32, 33) . Larson et al. (31) reported an attenuated mutator phenotype in cervical carcinoma, which suggests in cervical carcinogenesis an improbable MMR deficiency. By immunohistochemistry, in this preliminary study, we detected the absence of Msh2 and Mlh1 immunoreactivity in 1 of 14 (7.1%) and 4 of 14 (28.6%) cases, respectively, of NISCC. Conversely, in ISCC, it was found in 10 of 23 (43.5%) and 15 of 23 (65.2%) cases, respectively (Table 2)Citation . The lack of protein expression observed by immunohistochemistry in these cases could be speculative for somatic alterations in both Msh2 and Mlh1.

Alteration of the FHIT gene was observed in several types of carcinoma (34, 35, 36, 37, 38) . Aberrant FHIT transcripts were detected in cervical carcinoma cell lines and primary carcinomas (39) and correlated with a significant loss of Fhit protein by immunohistochemistry (37) . In previous studies, the loss of Fhit expression was detected in 33–76% of cervical carcinomas, whereas high levels of Fhit expression were detected in normal cervical epithelium but less frequently in squamous intraepithelial lesions (37 , 38 , 40, 41, 42) . Nakagawa et al. (43) suggest that the alteration of the FHIT gene may be an early genetic event during the generation of cervical carcinoma but not the consequence of cancer progression. On the other hand, Yoshino et al. (42) suggest that alterations of the FHIT gene can occur as later events in tumorigenesis. Hendricks et al. (44) reported abnormal Fhit expression in 63% of cervical cancer cell lines. Later, Birrer et al. (45) detected an abnormal staining in 61% of primary cervical cancer, confirming that FHIT gene dysfunction is a frequent event in cervical carcinoma. In agreement with Birrer et al. (45) in our study, we actually observed an absence of Fhit protein expression in 15 of 23 (65.2%) ISCCs and 8 of 14 (57.1%) NISCCs (Table 2)Citation . Moreover, we found that the Fhit protein was strongly expressed in dysplastic koilocytosis tissue but was reduced or actually disappeared in areas of invasive carcinoma (Fig. 2)Citation .

Recently, Sard et al. (46) found that the FHIT gene is apparently associated with a proapoptotic function. We observed a significant correlation between proapoptotic Bax and Fhit protein expression that was independent of tumor grading (P < 0.02).

In cervical cancer, the frequency of p53 mutation is rather low compared with mutations in other tumors, such as lung or colon carcinomas (47) . Different results concerning p53 protein expression percentage are reported in the literature. Rajkumar et al. (48) reported only 4 of 40 (10%) cases of SCC positive for p53 protein expression; Crawford et al. (49) observed 16 and 34% of cases p53 positive in cervical carcinoma using semiquantitative (cutoff at 5%) and quantitative methods of scoring, respectively.

Raju et al. (50) detected protein expression in 11 of 19 (58%) cases of SCC; Skomedal et al. (51) found elevated p53 protein in 41 of 74 cases (55%) of cervical cancer. Our study using a semiquantitative method (cutoff at 10%) indicated p53 protein overexpression in 16 of 23 (69.6%) cases of ISCCs and 4 of 14 (28.6%) cases of NISCC with a statistically significant correlation (P < 0.02; Table 3Citation ). The different percentage of p53 expression observed in literature could be explained by methodological differences, the type of antibody that recognizes wild-type and mutant p53, and different scoring and cutoff of the protein expression. Normal cervical epithelium adjacent to tumor did not stain p53 protein, which confirm reports by Cattoretti et al. (52) and Caamano et al. (53) that the steady-state level of normal p53 protein is too low to be detected immunohistochemically. A monoclonal antibody that recognized wild-type and mutant p53 (D07) was used. The wild form of p53 protein has a very short half-life, and it cannot be detected by immunohistochemistry (52, 53, 54) . However, overexpressed or mutated p53 proteins have a longer half-life and can recognized by immunohistochemistry (55) . Mutated p53 proteins complexed with other proteins, such as heat shock protein, may not be completely degraded by the protease system involving the gene E6 products of HPV and can be detected by immunohistochemistry (56) .

Msh2 and Mlh1 absence protein expression correlated with p53 overexpression as P < 0.001 and P < 0.001, respectively. No studies are reported in literature on the immunohistochemistry of MMR in cervical cancer; for this reason, verification of these preliminary findings in a much larger number of cases is necessary.

It is generally accepted that the potential of tumor progression is associated with the balance between cell death and cell proliferation and that the apoptotic process plays an important role in that balance. Members of the gene family that includes BCL-2 and BAX are involved in the control of apoptosis in a range of different cell types. Because BAX induces apoptosis and BCL-2 protects cells, it has been accepted that Bcl-2 and other members of the family compete to inactivate it through binding Bax (57) . It is commonly accepted that prolonged cell survival with inhibition of apoptosis is associated with carcinogenesis. Kokawa et al. (58) reported a large fraction of ISCCs immunonegative for Bcl-2, and Bax was detected weakly in a small fraction of ISCCs. Saegusa et al. (59) found that Bcl-2 immunoreactivity was significantly statistically correlated with CIN 3 in ISCC but not for Bax. We detected Bcl-2 expression in 15 of 23 (65.2%) of ISCCs and 2 of 14 (14.3%) NISCCs with a significant difference (P < 0.003). No correlation was found between Bax and NISCC and ISCC. No correlation was found between Bcl-2 and Bax expression.

Mutated p53 expression was found to be significantly associated with the loss of Msh2 and Mlh1 protein expression. In conclusion, these preliminary data indicate that the aberrant expression of Msh2, Mlh1, p53, and Bcl-2 could be involved in cervical cancer through NISCC to ISCC progression. FHIT gene alteration may play a role as a component of a proapoptotic pathway.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by Ministero dell’Università Ricerca Scientifica e Tecnologica 1996 funds. Back

2 To whom requests for reprints should be addressed, at II Facoltà di Medicina, Università degli studi di Roma La Sapienza, Piazza Sassari 3, 00161 Rome, Italy. Fax: 39-06-49973171; E-mail:a_vecchione{at}axrma.uniroma1.it Back

3 The abbreviations used are: HPV, human papillomavirus; MMR, mismatch repair; Fhit, fragile histidine triad; NISCC, noninvasive squamous cell carcinoma; ISCC, invasive SCC. Back

Received 3/20/00; revised 6/15/00; accepted 6/23/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brinton, L. A. Epidemiology of cervical cancer. Overview. In: N. Munoz, F. X. Bosch, K. V. Shah, and A. Meheus (eds.), Epidemiology of Cervical Cancer and Human Papillomavirus, pp. 2–23. IARC Scientific Publication No. 119. Lyon, France: IARC, 1992.
  2. The Revised Bethesda System for reporting cervical/vaginal cytological diagnoses: report of the 1991 Bethesda workshop. Acta Cytol., 36: 273–276, 1992.
  3. Parker M. F., Arroyo G. F., Gerardts J., Sabichi A. L., Park R. C., Taylor R. R. Molecular characterization of adenocarcinoma of the cervix. Gynecol. Oncol., 64: 242-251, 1997.[CrossRef][Medline]
  4. Nguyen H. N., Nordquist S. R. The Bethesda system and evaluation of abnormal pap smears. Semin. Surg. Oncol., 16: 217-221, 1999.[CrossRef][Medline]
  5. McLachin C. M., Tate J. E., Zitz J. C., Sheets E. E., Crum C. P. Human papillomavirus type 18 and intraepithelial lesions of the cervix. Am. J. Pathol., 144: 141-147, 1994.[Abstract]
  6. Paquette R. L., Lee Y. Y., Wilczynsky S. P., Karmakar A., Kizaki M., Miller C. W. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer (Phila.), 72: 1272-1280, 1993.[CrossRef][Medline]
  7. Spriggs A. L., Boddington M. M. Progression and regression of cervical lesions: review of smears from women followed without initial biopsy or treatment. J. Clin. Pathol., 33: 517-522, 1980.[Abstract/Free Full Text]
  8. Brescia R. J., Jenson A. B., Lancaster W. D., Kurman R. J. The role of human papillomaviruses in the pathogenesis and histologic classification of precancerous lesions of the cervix. Hum. Pathol., 17: 552-559, 1986.[Medline]
  9. Aaltonen L. A., Peltomaki P., Leach F. S. Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC), 260: 812-816, 1993.[Abstract/Free Full Text]
  10. Fishel R., Lescoe M. K., Rao M. R. S. The human mutator gene homologue MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75: 1027-1038, 1993.[CrossRef][Medline]
  11. Parsons R., Li G., Longley M. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell, 75: 1227-1236, 1993.[CrossRef][Medline]
  12. Leach F. S., Nicolaides N. C., Papadopulos N. Mutations of a mutS homologue in hereditary nonpolyposis colorectal cancer. Cell, 75: 1215-1226, 1993.[CrossRef][Medline]
  13. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C. M., Huebner K. The FHIT gene, spanning the chromosome 3p14. 2 fragile site and renal carcinoma-associated t(3;8) breakpoint, isabnormalindigestivetractcancers.Cell,84: 587-597, 1996.
  14. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C. M. The FHIT gene at 3p14. 2 is abnormal in breast carcinomas. Cancer Res., 56: 3173-3179, 1996.[Abstract/Free Full Text]
  15. Myashita T., Krajewski S., Krajewska M., Wang H., Lin H. K., Hoffman B., Lieberman D., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.[Medline]
  16. Yin Y., Tainsky M. A., Bischoff F. Z., Strong L. C., Wahl G. M. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948, 1992.[CrossRef][Medline]
  17. Nakano R. Apoptosis: gene-directed cell death. An Overview. Horm. Res., 48(Suppl.3): 2-4, 1997.
  18. Kerr J. F. R., Winterford C. M., Harmon B. V. Apoptosis: its significance in cancer and cancer therapy. Cancer (Phila.), 73: 2013-2026, 1994.[CrossRef][Medline]
  19. Tsujmoto Y., Croce C. M. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA, 83: 5214-5218, 1986.[Abstract/Free Full Text]
  20. Reed J. C. Bcl-2 and regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.[Free Full Text]
  21. Young E., Zha J., Jockel J., Boise L. H., Thompson C. B., Korsmeyer S. J. Bad, a heterodimeric partner for bcl-XL and bcl-2, displaces bax and promotes cell death. Cell, 80: 285-291, 1995.[CrossRef][Medline]
  22. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homologue, BAX, that accelerates programmed cell death. Cell, 74: 609-619, 1993.[CrossRef][Medline]
  23. Joensuu H., Pylkkanen L., Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am. J. Pathol., 145: 1191-1198, 1994.[Abstract]
  24. Kinzler W. K., Vogelstein B. Landscaping the cancer terrain. Science (Washington DC), 280: 1036-1037, 1998.[Free Full Text]
  25. Reitmair A. H., Cai J-C., Bjerknes M., Redston M., Cheng H., Pind M. T. L., Hay K., Mitri A., Bapat B. V., Mak T. W., Gallinger S. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res., 56: 2922-2926, 1996.[Abstract/Free Full Text]
  26. Baross F. A., Andrew S. E., Penney J. E., Jirik F. R. Tumors of DNA mismatch repair deficient hosts exhibit dramatic increases in genomic instability. Proc. Natl. Acad. Sci. USA, 95: 8739-8743, 1998.[Abstract/Free Full Text]
  27. Leach F. S., Polyak K., Burrell M., Johnson K. A., Hill D., Dunlop M. G., Wyllie A. H., Peltomaki P., de la Chapelle A., Hamilton S. R., Kinzler K. W., Vogelstein B. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissue. Cancer Res., 56: 235-240, 1996.[Abstract/Free Full Text]
  28. Thibodeau S. N., French A. J., Roche P. C., Cunningham J. M., Tester D. J., Lindor N. M., Moslein G., Baker S. M., Liskay R. M., Burgart L. J., Honchel R., Halling K. C. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res., 56: 4836-4840, 1996.[Abstract/Free Full Text]
  29. Helland A., Borresen-Dale A., Peltomaky P., Kristensen M., Nesland J. M., De La Shapelle A., Lothe R. A. Microsatellite instability in cervical and endometrial carcinomas. Int. J. Cancer, 70: 499-501, 1997.[CrossRef][Medline]
  30. Ku W. H., Liu I. L., Yen M. S., Chien C. C., Yue C. T., Ma Y., Chang S., Ng H., Wu C., Shen C. Genomic deletion and p53 inactivation in cervical carcinoma. Int. J. Cancer, 72: 270-276, 1997.[CrossRef][Medline]
  31. Larson A. A., Kern S., Sommers R. L., Yokota J., Cavenee W. K., Hampton G. M. Analysis of replication error (RER+) phenotypes in cervical carcinoma. Cancer Res., 56: 1426-1431, 1996.[Abstract/Free Full Text]
  32. Chung T. Y., Shen C. Y., Lee H. S., Liu H. S. Monoclonality and surface lesion-specific microsatellite alterations in premalignant and malignant neoplasia of uterine cervix: a local field effect of genomic instability and clonal evolution. Genes Chromosomes Cancer, 24: 127-134, 1999.[CrossRef][Medline]
  33. Mitra A. B., Murty V. V. V. S., Singh V., Li R. G., Pratap M., Sodhani P., Luthra U. K., Chaganti R. S. K. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J. Natl. Cancer Inst., 87: 742-745, 1995.[Abstract/Free Full Text]
  34. Sozzi G., Veronese M. L., Negrini M., Baffa R., Cotticelli M. G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U., Pierotti M. A., Otha M., Huebner K., Croce C. M. The FHIT gene at 3p14. 2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.[CrossRef][Medline]
  35. Druck T., Hadaczek P., Fu T-B., Otha M., Siprashvili Z., Baffa R., Negrini M., Kastury K., Veronese M. L., Rosen D., Rothstein J., McCue P., Cotticelli M. G., Inoue H., Croce C. M., Huebner K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res., 57: 504-512, 1997.[Abstract/Free Full Text]
  36. Virgilio L., Shuster M., Gollin S. M., Veronese M. L., Otha M., Huebner K., Croce C. M. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA, 93: 9770-9775, 1996.[Abstract/Free Full Text]
  37. Greenspan D. L., Connolly D. C., Wu R., Lei R. Y., Volgestein J. T. C., Kim Y-T., Mok J. E., Muñoz N., Bosch F. X., Shah K., Cho K. R. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res., 57: 4692-4698, 1997.[Abstract/Free Full Text]
  38. Croce C. M., Sozzi G., Huebner K. Role of FHIT in human cancer. J. Clin. Oncol., 17: 1618-1624, 1999.[Abstract/Free Full Text]
  39. Muller C. Y., O’ Boile J. D., Fong K. M., Wistuba I. I., Biesterveld E., Ahmadian M., Miller D. S., Gazdar A. F., Minna J. D. Abnormalities of fragile histidine triad genomic and complementary DNA in cervical cancer: association with human papilloma virus type. J. Natl. Cancer Inst., 90: 433-439, 1998.[Abstract/Free Full Text]
  40. Baffa R., Veronese M. L., Santoro R., Mandes B., Palazzo J. P., Rugge M., Santoro E., Croce C. M., Huebner K. Loss of FHIT expression in gastric carcinoma. Cancer Res., 58: 4708-4714, 1998.[Abstract/Free Full Text]
  41. Wistuba I. I., Montellano F. D., Milchgrub S., Virmani A. K., Behrens C., Chen H., Ahmadian M., Nowak J. A., Muller C., Minna J. D., Gazdar A. F. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res., 57: 3154-3158, 1997.[Abstract/Free Full Text]
  42. Yoshino K., Enomoto T., Nakamura T., Nakashima R., Wada H., Saitoh J., Noda K., Murata Y. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int. J. Cancer, 76: 176-181, 1998.[CrossRef][Medline]
  43. Nakagawa S., Yoshikawa H., Kimura M., Kawana K., Matsumoto K., Onda T., Kino N., Yamada M., Yasugi T., Taketani Y. A possible involvement of aberrant expression of the FHIT gene in the carcinogenesis of squamous cell carcinoma of the uterine cervix. Br. J. Cancer, 79: 589-594, 1999.[CrossRef][Medline]
  44. Hendricks D. T., Taylor R., Reed M., Birrer M. J. FHIT gene expression in human ovarian, endometrial, and cervical cell lines. Cancer Res., 57: 2112-2115, 1997.[Abstract/Free Full Text]
  45. Birrer M. J., Hendricks D. T., Farley J., Sundborg M. J., Bonome T., Walts M. J., Geradts J. Abnormal Fhit expression in malignant and premalignant lesion of the cervix. Cancer Res., 59: 5270-5274, 1999.[Abstract/Free Full Text]
  46. Sard L., Accornero P., Tornielli S., Delia D., Bunone G., Campiglio M., Colombo M. P., Gramegna M., Croce C. M., Pierotti M. A., Sozzi G. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc. Natl. Acad. Sci. USA, 96: 8489-8492, 1999.[Abstract/Free Full Text]
  47. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.[Free Full Text]
  48. Rajkumar T., Rajan S., Barruah R. K., Majhi U., Selvaluxmi G., Vasanthan A. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. Eur. J. Gynaecol. Oncol., 19: 556-560, 1998.[Medline]
  49. Crawford R., Caldwell C., Iles R. K., Lowe D., Shepherd J. H., Chad T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br. J. Cancer, 78: 210-214, 1998.[Medline]
  50. Raju G. C., Teh M., Wee A. An immunohistochemical study of p53 protein in cervical intraepithelial neoplasia and squamous cell carcinoma. Pathology, 28: 17-19, 1996.[CrossRef][Medline]
  51. Skomedal H., Kristensen G. B., Lie A. K., Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol., 73: 223-228, 1999.[CrossRef][Medline]
  52. Cattoretti G., Rilke F., Andreola S., D’Amato L., Delia D. p53 expression in breast cancer. Int. J. Cancer, 41: 178-183, 1988.[Medline]
  53. Caamano J., Ruggeri B., Momiki S., Sickler A., Zhang S. Y., Klein-Szanto A. J. P. Detection of p53 in primary lung tumors and non-small cell lung carcinoma cell lines. Am. J. Pathol., 139: 839-845, 1991.[Abstract]
  54. Gronostajski R. M., Goldberg A. L., Pardee A. B. Energy requirement for degradation of tumor-associated protein p53. Mol. Cell. Biol., 4: 442-448, 1984.[Abstract/Free Full Text]
  55. Finlay C. A., Hinds P. W., Tan T-H., Eliyahu D., Oren M., Levine A. J. Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 with an altered half-life. Mol. Cell. Biol., 8: 531-539, 1988.[Abstract/Free Full Text]
  56. Akasofu M., Oda Y. Immunohistochemical detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18. Virchows Arch. A Pathol. Anat. Hist., 425: 593-602, 1995.
  57. Sedlack T. W., Oltvai Z. N., Yang E., Wang K., Boise L. H., Thompson C. B., Korsmeyer S. J. Multiple bcl-2 family members demonstrate selective dimerisation with bax. Proc. Natl. Acad. Sci. USA, 92: 7834-7838, 1995.[Abstract/Free Full Text]
  58. Kokawa K., Shikone T., Otani T., Nakano R. Apoptosis and the expression of Bax and Bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Cancer (Phila.), 85: 1799-1809, 1999.[CrossRef][Medline]
  59. Saegusa M., Takano Y., Hashimura M., Shoji Y., Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer (Phila.), 76: 2297-2303, 1995.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
E R Nijhuis, H W Nijman, K A Oien, A Bell, K A ten Hoor, N Reesink-Peters, H M Boezen, H Hollema, and A G J van der Zee
Loss of MSH2 protein expression is a risk factor in early stage cervical cancer
J. Clin. Pathol., July 1, 2007; 60(7): 824 - 830.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Ishii, K. R. Dumon, A. Vecchione, L. Y. Y. Fong, R. Baffa, K. Huebner, and C. M. Croce
Potential Cancer Therapy With the Fragile Histidine Triad Gene: Review of the Preclinical Studies
JAMA, November 21, 2001; 286(19): 2441 - 2449.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mori, K. Mimori, T. Masuda, K. Yoshinaga, K. Yamashita, A. Matsuyama, and H. Inoue
Absence of Msh2 Protein Expression Is Associated with Alteration in the FHIT Locus and Fhit Protein Expression in Colorectal Carcinoma
Cancer Res., October 1, 2001; 61(20): 7379 - 7382.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online